News and Events
April 04, 2023 Press
Indivumed Evolves into Indivumed Therapeutics to Focus on Data and AI-Driven Advancement of Precision Oncology
Sale of Indivumed’s Service Business to Crown Bioscience Enables Creation of Oncology R&D Powerhouse
Indivumed Evolves into Indivumed Therapeutics to Focus on Data and AI-Driven Advancement of Precision Oncology Read moreJanuary 25, 2023 Press
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A Sales and Purchase Agreement (SPA) between both parties was executed on December 29, 2022, and subject to customary closing adjustments the transaction is expected to close in April 2023.
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank Read moreDecember 23, 2022 Press
Ending the year - Today. Tomorrow. Together.
A review on 2022 and Indivumed's 20 year long history, and outlook, and thank you
Ending the year - Today. Tomorrow. Together. Read moreSeptember 07, 2022 Press
Indivumed and CELLphenomics Announce Partnership
Indivumed GmbH and CELLphenomics GmbH today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.
Indivumed and CELLphenomics Announce Partnership Read more
RESEARCH PUBLICATIONS & Posters
Video
Indivumed Therapeutics:
Data-driven precision oncology
Introducing:
Indivumed Therapeutics, April 2023
In Focus:
The Future of Indivumed – Interview with Prof. Dr. Hartmut Juhl, Indivumed Therapeutics
In Focus:
Therapeutic target Identification – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Clinical Network – Interview with Dr. Susanne Arbogast, Indivumed Therapeutics
In Focus:
nRavel – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Data Depth – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Data Quality – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Our Vision – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
AI – Interview with John L. Marshall, MD, Georgetown University Hospital
In Focus:
Precision Oncology – Interview with John L. Marshall, MD, Georgetown University Hospital